Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy

Richard Burwick, Kelly Kuo, Diana Brewer, Brian Druker

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited. CASE: We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-a were initiated in the second trimester with limited benefit. Imatinib was subsequently started at 28 weeks of gestation with complete hematologic response within 4 weeks. No significant maternal or neonatal adverse effects were noted, but imatinib and its primary active metabolite concentrated in maternal breast milk and neonatal urine. CONCLUSION: Imatinib is effective for CML in pregnancy, but caution is warranted in light of potentially unrecognized fetal and neonatal effects.

Original languageEnglish (US)
Pages (from-to)831-834
Number of pages4
JournalObstetrics and Gynecology
Volume129
Issue number5
DOIs
StatePublished - 2017

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mothers
Pregnancy
Leukapheresis
Second Pregnancy Trimester
Human Milk
Therapeutics
Protein-Tyrosine Kinases
Interferons
Pregnant Women
Urine
Safety
Imatinib Mesylate

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy. / Burwick, Richard; Kuo, Kelly; Brewer, Diana; Druker, Brian.

In: Obstetrics and Gynecology, Vol. 129, No. 5, 2017, p. 831-834.

Research output: Contribution to journalArticle

@article{48f7795fc3634082867a63eae0816d15,
title = "Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy",
abstract = "BACKGROUND: Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited. CASE: We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-a were initiated in the second trimester with limited benefit. Imatinib was subsequently started at 28 weeks of gestation with complete hematologic response within 4 weeks. No significant maternal or neonatal adverse effects were noted, but imatinib and its primary active metabolite concentrated in maternal breast milk and neonatal urine. CONCLUSION: Imatinib is effective for CML in pregnancy, but caution is warranted in light of potentially unrecognized fetal and neonatal effects.",
author = "Richard Burwick and Kelly Kuo and Diana Brewer and Brian Druker",
year = "2017",
doi = "10.1097/AOG.0000000000001972",
language = "English (US)",
volume = "129",
pages = "831--834",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy

AU - Burwick, Richard

AU - Kuo, Kelly

AU - Brewer, Diana

AU - Druker, Brian

PY - 2017

Y1 - 2017

N2 - BACKGROUND: Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited. CASE: We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-a were initiated in the second trimester with limited benefit. Imatinib was subsequently started at 28 weeks of gestation with complete hematologic response within 4 weeks. No significant maternal or neonatal adverse effects were noted, but imatinib and its primary active metabolite concentrated in maternal breast milk and neonatal urine. CONCLUSION: Imatinib is effective for CML in pregnancy, but caution is warranted in light of potentially unrecognized fetal and neonatal effects.

AB - BACKGROUND: Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited. CASE: We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-a were initiated in the second trimester with limited benefit. Imatinib was subsequently started at 28 weeks of gestation with complete hematologic response within 4 weeks. No significant maternal or neonatal adverse effects were noted, but imatinib and its primary active metabolite concentrated in maternal breast milk and neonatal urine. CONCLUSION: Imatinib is effective for CML in pregnancy, but caution is warranted in light of potentially unrecognized fetal and neonatal effects.

UR - http://www.scopus.com/inward/record.url?scp=85017091406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017091406&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000001972

DO - 10.1097/AOG.0000000000001972

M3 - Article

VL - 129

SP - 831

EP - 834

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 5

ER -